Trial Profile
A Multicenter, Randomized, Open-label, Blinded-assessor, Follow-up, Phase 4 Study in Patients With Rheumatoid Arthritis Who Have Completed the Initial Treatment Part in the NORD-STAR Study and Have Reached Stable Low Disease Activity
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Jul 2022
Price :
$35
*
At a glance
- Drugs Abatacept (Primary) ; Certolizumab pegol (Primary) ; Tocilizumab (Primary) ; Azathioprine; Leflunomide; Methotrexate
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms CO-STAR
- 07 Jul 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2023.
- 07 Jul 2022 Planned primary completion date changed from 1 Mar 2021 to 22 Jul 2023.
- 28 Oct 2021 Status changed from active, no longer recruiting to completed.